Table 3

Biomarkers’ change from baseline to week 24 between the second TNFi and tocilizumab groups

Second TNFi (n=96)Tocilizumab (n=47)P-value second TNFi versus tocilizumab*
ApoA1 (g/L)Median baseline (IQR)1.74 (1.54 to 2.03)1.6 (1.5 to 1.89)
Median change (IQR)0.03 (−0.12 to 0.16)0.06 (−0.07 to 0.27)0.09
P-value of change W24 versus baseline†<0.001<0.001
Median % of change (IQR)1.23 (−6.13 to 9.84)3.45 (−4.9 to 19.2)
ApoB100 (g/L)Median baseline (IQR)1.01 (0.87 to 1.16)1.04 (0.88 to 1.2)
Median change (IQR)−0.01 (−0.09 to 0.08)0.08 (−0.14 to 0.19)0.051
P-value of change W24 versus baseline‡0.5360.206
Median % of change (IQR)−1.2 (−9.35 to 7.45)6.67 (−13.46 to 17.12)
ApoB100/ApoA1 ratioMedian baseline (IQR)0.54 (0.46 to 0.69)0.65 (0.47 to 0.75)0.13
Median change (IQR)−0.01 (−0.08 to 0.05)0.01 (−0.07 to 0.09)
P-value of change W24 versus baseline‡0.1560.968
Median % of change (IQR)−2.09 (−12.97 to 9.76)1.43 (−12.07 to 15.67)
Lp(a) (g/L)Median baseline (IQR)0.10 (0.05 to 0.29)0.18 (0.07 to 0.31)
Median change (IQR)−0.01 (−0.02 to 0.01)−0.05 (−0.11 to −0.01)0.0001
P-value of change W24 versus baseline‡0.058<0.001
Median % of change (IQR)−1.72 (−22.74 to 8.62)−28.57 (−44 to −1.28)
Leptin (ng/mL)Median baseline (IQR)9.90 (5.22 to 22)11.74 (5.9 to 25.57)
Median change (IQR)0.47 (−2.1 to 2.56)−0.71 (−5.13 to 3.47)0.46
P-value of change W24 versus baseline‡0.4190.406
Median % of change (IQR)5.62 (−22.72 to 33.95)−7.25 (−32.61 to 28.35)
Adiponectin (mg/L)Median baseline (IQR)7.25 (5 to 9.93)7.92 (5.24 to 10.26)
Median change (IQR)0.1 (−0.63 to 0.79)0.46 (−0.43 to 1.33)0.10
P-value of change W24 versus baseline‡0.5050.024
Median % of change (IQR)1.35 (−7.85 to 11.61)5.7 (−5.35 to 17.28)
Leptin/adiponectin ratio (ng/µg)Median baseline (IQR)1.55 (0.62 to 2.82)1.64 (0.87 to 3.51)
Median change (IQR)0.04 (−0.19 to 0.43)−0.028 (−0.66 to 0.41)0.26
P-value of change W24 versus baseline‡0.2170.325
Median % of change (IQR)3.64 (−17.91 to 36.14)−9.18 (−33.11 to 37.54)
  • Statistical analysis.

  • *ANCOVA model.

  • †Paired Student’s t-test.

  • ‡Wilcoxon signed rank test.

  • ANCOVA, analysis of covariance; Apo, apolipoprotein; Lp(a), lipoprotein(a); TNFi, tumour necrosis factor inhibitor; W24, week 24.